GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
NCT00905255 on ClinicalTrials.gov · last registry update 2016-12-21
A small phase 3 — 69 participants, against a typical 424. Completed January 2011. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- COMPLETED
- Phase
- P3
- Drug
- lixisenatideSoliqua, Adlyxin
- Sponsor
- Sanofi
- Sponsor type
- Industry
- Enrollment
- 69
- Started
- 2009-05
- Primary completion
- 2011-01 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-21 | First seen in registry | Registered as COMPLETED, P3 |
Primary outcome
Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.